Philip Kuebler J, Moore Timothy, Pritchard James, Kraut Eric
Grant/Riverside Hospitals, Columbus, Ohio, USA.
Invest New Drugs. 2004 Apr;22(2):181-4. doi: 10.1023/B:DRUG.0000011795.82694.80.
A phase II trial of CI-958 (NSC #635371), a new benzothiopyranoindazole was performed in patients with hormone refractory prostate carcinoma using prostate specific antigen (PSA) levels for response assessment. Twenty-two patients were entered on this study and twenty one were eligible. Toxicity consisted mainly of granulocytopenia (71% grade 3 or 4), but there were no significant infections. Two patients were removed from study due to asymptomatic decreases in cardiac ejection fraction. Of 21 evaluable patients, there were four responders (19%, CI 0-35%).
一项针对新型苯并噻吩并吲哚CI-958（NSC #635371）的II期试验在激素难治性前列腺癌患者中进行，使用前列腺特异性抗原（PSA）水平进行疗效评估。22名患者进入该研究，21名符合条件。毒性主要包括粒细胞减少（71%为3级或4级），但无严重感染。两名患者因无症状的心脏射血分数下降而退出研究。在21名可评估患者中，有4名缓解者（19%，可信区间0-35%）。
